2009-03-13 00:06:05 -
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced that Howard Weisman, the Company’s Chairman and Chief Executive Officer, has been invited to present at the Cowen and Company 29th Annual Health Care Conference.
The Conference will take place at The Boston Marriott Copley Place March 16-19, 2009. Weisman will present an overview
of EKR and its core hospital products including DepoDur® and recently approved Cardene® I.V.
Ready-to-Use premixed intravenous bags. The EKR presentation is scheduled for Tuesday, March 17 from 11:00 – 11:25 AM ET.
About EKR Therapeutics
EKR Therapeutics, with 2008 revenues surpassing the $200 million level, is a rapidly emerging specialty pharmaceutical company focused on identifying, fostering and targeting the growth of novel acute-care hospital products to improve outcomes and patient quality of life. The Company’s growing portfolio of products include: Cardene ® I.V. (nicardipine hydrochloride) premixed injection, Retavase ® (reteplase recombinant), DepoDur ® (morphine sulfate extended-release liposomal injection), and Gelclair ® (bioadherent oral gel). For additional information about EKR visit
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
Full prescribing and other information about Cardene I.V. and DepoDur are available, respectively, at
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. and
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
EKR TherapeuticsStuart Z. Levine, Ph.D., 877-435-2524Director,
Corporate Communications/IR mailto:s.levine@ekrtx.com
